pegfilgrastim Archives | Page 5 of 16

Sandoz Canada enters agreement with pCPA for Ziextenzo® and Riximyo®

by Bioblast Editor | Aug 19, 2020 | Biosimilars updates

Sandoz Canada announces it has entered an agreement with the Pan-Canadian Pharmaceutical Alliance (pCPA) regarding biosimilar medicines Ziextenzo® (biosimilar pegfilgrastim) and Riximyo® (biosimilar rituximab). Both products were approved by Health Canada in late...

Pfizer Q2 FY20 financial results released

by Bioblast Editor | Jul 28, 2020 | Biosimilars updates

Pfizer releases its Q2 FY20 financial results. Pfizer reveals that it plans to launch Nyvepria® (biosimilar pegfilgrastim) in the US later this year.

Results of study into Sandoz’s Ziextenzo® released

by Bioblast Editor | Jul 24, 2020 | Biosimilars updates

A new study published by the Journal of Clinical Pathways demonstrates significant cost-savings generated by Sandoz’s pegfilgrastim biosimilar Ziextenzo®.

FDA approves Pfizer’s Nyvepria®

by Bioblast Editor | Jun 11, 2020 | Biosimilars updates

Pfizer announces the FDA has approved Nyvepria® (pegfilgrastim). Nyvepria® is indicated to decrease the incidence of infection, manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs.

Sandoz granted marketing approval for Ziextenzo® and Riximyo®

by Bioblast Editor | Jun 9, 2020 | Biosimilars updates

Sandoz announces Health Canada has granted marketing approval for Ziextenzo® (pegfilgrastim) and Riximyo® (rituximab).